FDA investigates patient deaths after treatment with Sarepta's gene therapy

The FDA is investigating two deaths from acute liver failure in non-ambulatory Duchenne muscular dystrophy patients who received Sarepta Therapeutics' (NASDAQ: SRPT) gene therapy, Elevidys. Both patients, aged 15 and 16, died within 90 days of treatment, raising significant safety concerns and potentially impacting future demand for the only FDA-approved gene therapy for DMD, which already carries a known risk of liver damage.

Analysis

Sarepta Therapeutics (SRPT) is facing a significant regulatory and safety challenge as the U.S. FDA investigates two patient deaths from acute liver failure following treatment with its gene therapy, Elevidys. The investigation centers on two non-ambulatory Duchenne muscular dystrophy patients, aged 15 and 16, who died within 90 days of receiving the therapy. This development amplifies existing concerns, as Elevidys is already known to carry a risk of liver damage and Sarepta had previously disclosed the second death in June. As the only FDA-approved gene therapy for DMD in patients aged four and above, Elevidys is a pivotal asset for the company. The investigation therefore poses a direct threat to its commercial trajectory, potentially leading to revised safety warnings, a restricted patient label, or more severe regulatory actions that could curtail future demand and revenue projections. The strongly negative sentiment score of -0.75 and high market impact signal underscore the severity of this event for investor perception and the company's valuation.

Key Decisions for Investors

• Investors should closely monitor all communications from the FDA regarding its investigation, as any resulting regulatory action, such as a black box warning or label restriction, will materially impact SRPT's future earnings potential.
• Re-evaluate the commercial viability and peak sales forecasts for Elevidys, as these fatal adverse events could significantly limit physician and patient adoption, particularly in the non-ambulatory population.
• Given the high uncertainty and negative sentiment surrounding this key asset, consider adopting a cautious stance and prepare for heightened stock volatility until the full clinical and regulatory implications are clarified.